HomeDrug ClassesCD79b Antibodies

CD79b Antibodies: Uses, Common Brands, and Safety Info

CD79b antibodies target the CD79b protein on B cells and are used to treat B-cell malignancies, such as lymphoma and leukemia. Common brands include Polivy and Ukoniq. Safety precautions and potential side effects should be discussed with a healthcare professional.

CD79b Antibodies

CD79b antibodies are a class of medications that specifically target and bind to the CD79b protein, which is found on the surface of B cells. B cells are a type of white blood cell involved in the immune response. By inhibiting the activity of CD79b, these antibodies can modulate the immune system and have therapeutic effects in certain medical conditions.


CD79b antibodies have shown promise in the treatment of B-cell malignancies, particularly B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). These medications function by interfering with the signaling pathways of B cells, leading to reduced growth and survival of cancer cells. They may be used alone or in combination with other cancer treatments, such as chemotherapy or targeted therapies.

Common Brands

There are several CD79b antibodies available on the market, each with its specific name and brand. Examples of common CD79b antibodies include: 1. Polatuzumab vedotin - Brand name: Polivy 2. Umbralisib - Brand name: Ukoniq It is important to note that the availability and brand names of CD79b antibodies may vary depending on the country and local regulations. Always consult with a healthcare professional for up-to-date and accurate information regarding specific medications.


CD79b antibodies can have side effects, and it is essential to be aware of potential risks associated with their use. Common side effects may include fatigue, nausea, diarrhea, decreased appetite, and fever. In some cases, more serious adverse reactions, such as infusion-related reactions, infections, or liver toxicity, may occur. It is crucial to follow the prescribed dosage and monitoring guidelines provided by the healthcare provider to minimize potential risks. Before starting any medication, it is important to discuss your medical history, current medications, and any underlying conditions with your healthcare provider. They will be able to provide personalized guidance and evaluate whether CD79b antibodies are suitable for your specific situation. In summary, CD79b antibodies are a class of medications used in the treatment of B-cell malignancies, particularly B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. They function by targeting the CD79b protein on B cells, modulating immune responses. Common brands include Polivy (polatuzumab vedotin) and Ukoniq (umbralisib). Safety is an important consideration, and individuals should be aware of potential side effects and discuss their medical history with a healthcare professional.